Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes joint damage, pain, and disability, leading to significant impairments in patients' physical, mental, and social well-being. While biological disease-modifying antirheumatic drugs (bDMARDs) such as tumor necrosis factor (TNF) inhibitors, interleukin-6 (IL-6) inhibitors, and Janus kinase (JAK) inhibitors have revolutionized the treatment of RA by effectively controlling disease activity, their influence on patients' quality of life (QoL) is crucial but not fully understood. The aim of this review is to evaluate the impact of bDMARDs on QoL in RA patients, particularly focusing on domains such as physical functioning, pain, fatigue, mental health, and social participation. A comprehensive literature search was conducted in databases such as PubMed and the Cochrane Library, including randomized controlled trials, cohort studies, and surveys assessing QoL outcomes in RA patients receiving bDMARD therapy. The review includes studies that utilized the Health Assessment Questionnaire (HAQ), EuroQol-5 Dimension (EQ-5D), and Short Form-36 (SF-36), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Fatigue Severity Scale (FSS), and Patient Global Assessment (PtGA) QoL questionnaires, among others, to assess patient-reported outcomes. The findings of the current review suggest that bDMARDs significantly improve QoL in RA patients by reducing pain, fatigue, and disability while enhancing physical function and mental well-being. However, variability in patient responses, side effects, and the long-term impact of these therapies remain key concerns. Future studies with standardized QoL assessments and longer follow-up periods are needed to provide a more comprehensive understanding of the sustained effects of bDMARD therapy on RA patients' overall well-being.